> Detailanzeige

Caulier, Alexis; Roussel, Murielle; Morel, Pierre; Lombion, Naelle; Branco, Benoît; Galtier, Jean; Hulin, Cyrille; Perrot, Aurore; Richez, Valentine; Michaud, Anne-Victoire; Touzeau, Cyrille; Doyen, Chantal; Mariette, Clara; Caillot, Denis; Harel, Stéphanie; Lenain, Pascal; Ivanoff, Sarah; Fontan, Jean; Stoppa, Anne-Marie; Manier, Salomon; Garderet, Laurent; Leleu, Xavier; Marolleau, Jean-Pierre; Arnulf, Bertrand; [...]

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
  • Beteiligte: Caulier, Alexis; Roussel, Murielle; Morel, Pierre; Lombion, Naelle; Branco, Benoît; Galtier, Jean; Hulin, Cyrille; Perrot, Aurore; Richez, Valentine; Michaud, Anne-Victoire; Touzeau, Cyrille; Doyen, Chantal; Mariette, Clara; Caillot, Denis; Harel, Stéphanie; Lenain, Pascal; Ivanoff, Sarah; Fontan, Jean; Stoppa, Anne-Marie; Manier, Salomon; Garderet, Laurent; Leleu, Xavier; Marolleau, Jean-Pierre; Arnulf, Bertrand; [...]
  • Erschienen: American Society of Hematology, 2021
  • Erschienen in: Blood
  • Sprache: Englisch
  • DOI: 10.1182/blood.2021011285
  • ISSN: 0006-4971; 1528-0020
  • Schlagwörter: Cell Biology ; Hematology ; Immunology ; Biochemistry
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:p>Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing &amp;lt;2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age ≤40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P = .01), high ISS score (HR, 2.14; P = .03), and high-risk cytogenetics (HR, 4.54; P &amp;lt; .0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P &amp;lt; .0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sex-matched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.</jats:p>
  • Zugangsstatus: Freier Zugang